Pdt Partners, LLC Kal Vista Pharmaceuticals, Inc. Transaction History

Pdt Partners, LLC

$1 Billion
Q4 2024

A detailed history of Pdt Partners, LLC transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 35,201 shares of KALV stock, worth $431,212. This represents 0.03% of its overall portfolio holdings.

Number of Shares

35,201

Previous 22,454 56.77%

Holding current value

$431,212

Previous $260,000 14.62%

% of portfolio

0.03%

Previous 0.03%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$8.09 - $12.5 $103,123 - $159,337	12,747 Added 56.77%	35,201 $298,000
Q3 2024 Nov 14, 2024	BUY	$9.46 - $15.39 $212,414 - $345,567	22,454 New	22,454 $260,000
Q1 2024 May 15, 2024	BUY	$11.07 - $16.04 $464,397 - $672,894	41,951 New	41,951 $497,000
Q3 2023 Nov 14, 2023	BUY	$8.95 - $11.35 $4,009 - $5,084	448 Added 1.2%	37,754 $363,000
Q2 2023 Aug 14, 2023	SELL	$7.73 - $10.57 $270 - $369	-35 Reduced 0.09%	37,306 $335,000
Q1 2023 May 15, 2023	SELL	$6.3 - $8.39 $61,128 - $81,408	-9,703 Reduced 20.63%	37,341 $293,000
Q4 2022 Feb 14, 2023	BUY	$4.2 - $14.24 $197,584 - $669,906	47,044 New	47,044 $318,000
Q2 2022 Aug 15, 2022	BUY	$8.16 - $15.1 $115,162 - $213,106	14,113 New	14,113 $139,000
Q3 2020 Nov 16, 2020	SELL	$9.83 - $13.99 $160,474 - $228,386	-16,325 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$6.75 - $12.89 $20,081 - $38,347	-2,975 Reduced 15.41%	16,325 $198,000
Q1 2020 May 15, 2020	SELL	$5.8 - $18.56 $26,981 - $86,341	-4,652 Reduced 19.42%	19,300 $148,000
Q4 2019 Feb 14, 2020	BUY	$10.31 - $17.81 $246,945 - $426,585	23,952 New	23,952 $427,000

Others Institutions Holding KALV

# of Institutions

131

Shares Held

53.3M

Call Options Held

63.5K

Put Options Held

36.6K

View Full List

About KalVista Pharmaceuticals, Inc.

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $301M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

More about KALV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.

Account